Warnock will fight to lower prescription drug costs for families, including insulin costs.

Raphael G. Warnock · Georgia · Democratic

policy impact 0.78 specificity 0.68 extraction confidence 76%

Contest this claim

Occurrences

he’s also fighting to ... lower the cost of prescription drugs like insulin

The campaign says Warnock is fighting to lower prescription drug costs, naming insulin as an example.

Cutting Costs - Warnock for Georgia
campaign · campaign_site · model gpt-5.5

Evidence

Reverend Warnock is fighting to lower the cost of prescription drugs for hardworking families, including lowering the cost of prescription drugs like insulin.

Campaign material states the promise directly: lower prescription drug costs, including insulin.

partial same_term

Cutting Costs - Warnock for Georgia
campaign · model gpt-5.4-mini · confidence 95%

Contest this evidence item

Sponsor: Sen. Warnock, Raphael G. [D-GA] (Introduced 02/11/2025). The bill is titled the Capping Prescription Costs Act of 2025 and seeks to limit cost-sharing for prescription drugs.

Warnock introduced legislation to cap prescription drug costs in his Senate service, showing continued concrete action on the pledge.

partial same_term A for effort

S.529 - Capping Prescription Costs Act of 2025
secondary · model gpt-5.4-mini · confidence 98%

Contest this evidence item

The legislation would cap annual out-of-pocket prescription drug costs per year at $2,000 for individuals and $4,000 for families with private insurance.

Warnock advanced a concrete prescription-drug-cost cap for families, but it remained a proposal rather than enacted law.

partial same_term A for effort

Senator Reverend Warnock Introduces Legislation to Cap the Cost of Prescription Medication
secondary · model gpt-5.4-mini · confidence 97%

Contest this evidence item

Section 11406 creates appropriate cost-sharing for covered insulin products under Medicare Part D, including no deductible and cost-sharing not to exceed the applicable copayment amount for a month’s supply.

The enacted law included a 35-dollar insulin cost cap for Medicare Part D beneficiaries, confirming part of the promise was delivered.

delivered same_term

Public Law 117-169
secondary · model gpt-5.4-mini · confidence 99%

Contest this evidence item

Vote Result: Passed. Question: On Passage of the Bill: H.R. 5376, As Amended. This was the Senate’s final passage vote on the Inflation Reduction Act package that carried the insulin and prescription-drug provisions.

Warnock’s Senate backed the final law vehicle that delivered insulin savings and broader prescription-drug reforms.

delivered same_term

U.S. Senate Roll Call Vote 117th Congress - 2nd Session, Vote 325
secondary · model gpt-5.4-mini · confidence 94%

Contest this evidence item

The law provides a yearly cap ($2,000 in 2025) on out-of-pocket prescription drug costs in Medicare and says people with Medicare who take insulin covered by their prescription drug plan will have access to each insulin for no more than $35 for a month’s supply.

Federal implementation guidance confirms the law lowered prescription drug costs and capped insulin costs, but mainly for Medicare beneficiaries rather than all families.

partial same_term

CMS Fact Sheet: The Inflation Reduction Act Lowers Health Care Costs for Millions of Americans
secondary · model gpt-5.4-mini · confidence 98%

Contest this evidence item

Assessments

delivered same_term

Warnock promised to fight to lower prescription drug costs, including insulin. During his Senate term, the Inflation Reduction Act passed with his chamber support and enacted major prescription-drug reforms, including a $35 monthly insulin cap for Medicare beneficiaries and a $2,000 annual Medicare out-of-pocket prescription-drug cap beginning in 2025. The delivery was not universal for all families or all private insurance insulin users, but the pledge was framed as fighting to lower costs rather than guaranteeing a comprehensive universal cap, and a substantial federal prescription-drug and insulin-cost reduction became law in the same term. His later sponsorship of broader prescription-cost cap legislation reinforces continued effort but is not needed for the core delivery finding.

provider codex_cli · model gpt-5.5 · confidence 86%